Cellectis SA (NASDAQ:CLLS) Sees Significant Drop in Short Interest

Cellectis SA (NASDAQ:CLLS) was the recipient of a large decrease in short interest in January. As of January 15th, there was short interest totalling 245,100 shares, a decrease of 22.7% from the December 31st total of 316,900 shares. Based on an average trading volume of 120,300 shares, the days-to-cover ratio is presently 2.0 days. Approximately 0.6% of the company’s stock are short sold.

Hedge funds have recently modified their holdings of the company. Lindbrook Capital LLC raised its stake in shares of Cellectis by 164.6% during the 4th quarter. Lindbrook Capital LLC now owns 2,008 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 1,249 shares during the last quarter. Rhenman & Partners Asset Management AB purchased a new position in shares of Cellectis during the 4th quarter worth approximately $2,476,000. Point72 Asset Management L.P. boosted its holdings in Cellectis by 32.6% during the third quarter. Point72 Asset Management L.P. now owns 189,000 shares of the biotechnology company’s stock worth $1,966,000 after buying an additional 46,500 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its position in Cellectis by 8.6% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,314,295 shares of the biotechnology company’s stock worth $13,669,000 after purchasing an additional 104,276 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. grew its position in shares of Cellectis by 7.3% in the third quarter. Nikko Asset Management Americas Inc. now owns 1,314,295 shares of the biotechnology company’s stock valued at $13,669,000 after purchasing an additional 89,961 shares during the last quarter. Institutional investors own 31.31% of the company’s stock.

NASDAQ CLLS opened at $16.50 on Wednesday. Cellectis has a 52-week low of $9.50 and a 52-week high of $20.84. The company has a 50-day simple moving average of $17.45 and a 200 day simple moving average of $13.88. The company has a debt-to-equity ratio of 0.12, a quick ratio of 7.93 and a current ratio of 7.99. The company has a market capitalization of $695.76 million, a PE ratio of -8.01 and a beta of 1.88.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.51. The business had revenue of $10.21 million for the quarter, compared to analyst estimates of $1.40 million. Cellectis had a negative net margin of 446.75% and a negative return on equity of 21.03%. As a group, analysts forecast that Cellectis will post -2.37 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Zacks Investment Research upgraded shares of Cellectis from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a report on Tuesday, January 7th. William Blair restated a “buy” rating on shares of Cellectis in a report on Monday, January 13th. BidaskClub downgraded shares of Cellectis from a “buy” rating to a “hold” rating in a research report on Friday, January 24th. Finally, Nomura reiterated a “buy” rating and issued a $73.00 price objective on shares of Cellectis in a research note on Monday, December 16th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $36.83.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.

Featured Article: Percentage Decliners

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.